Neuren Partner Acadia Signs Japan Distribution Deal for DAYBUE STIX
NEU: $22.74 -1.04% · MC: $2.9B
Neuren Pharmaceuticals’ partner Acadia has signed an exclusive agreement with KYORIN Pharmaceutical to commercialise DAYBUE STIX in Japan. Acadia anticipates a regulatory filing in 2027 and a potential launch in 2028, subject to approval; it had previously said it was seeking a distribution partner. Neuren is entitled to US$15 million after the first commercial sale, potential sales milestones of up to US$110 million and tiered royalties.

Comments